⚡ Sp Key Summary
Big Tech titans, led by Peter Thiel, define death as a biological limitation and are pouring massive capital into biotechnology startups to overcome it.
While research into cellular reprogramming using Yamanaka factors and AI-driven longevity studies is actively progressing, the accumulation of somatic mutations imposes a fundamental ceiling on the maximum human lifespan.
Given the rapid pace of global aging and the enormous socioeconomic burden of age-related diseases, aging-delay technology is regarded as a massive market with limitless potential.
What is the longest-living animal in the world? Could it be the turtle or the crane, celebrated in East Asian tradition among the Ten Longevity Symbols? Or perhaps colossal creatures like elephants or whales? Of course, there are also organisms such as the 'hydra,' which can constantly regenerate and are theoretically immortal. But what if we set aside such outliers? A surprisingly familiar animal takes first place.
We ranked the longest-living animals based on a database maintained by an animal aging biology research team in the United Kingdom. The longest-living animal on Earth is the glass sponge, which lives in polar regions such as Antarctica. It is estimated to survive for up to 15,000 years. These sea sponges are the very relatives of the kitchen cleaning tools we use every day, as well as the inspiration behind the cartoon character SpongeBob SquarePants.
Among bivalve mollusks, an ocean quahog clam has been recorded to reach an age of approximately 507 years. Because it was born around 500 years ago during China's Ming Dynasty, this individual clam was even nicknamed 'Ming.'
The longest-living animal among all vertebrates is the Greenland shark, with an estimated maximum lifespan of about 392 years.
Among mammals, the bowhead whale holds the record, living for more than 211 years.
How about humanity? The longest-lived human whose record has been officially verified is Jeanne Calment of France. Born on February 21, 1875, she died on August 4, 1997, living for a total of 122 years and 164 days. Having lived for over 120 years, she celebrated the milestone equivalent of two full 60-year life cycles. During her lifetime, she even met Vincent van Gogh in person. Calment outlived her only daughter and grandson, bidding farewell to all her precious family members before meeting her own end. Perhaps because of that, it is said that she passed away viewing death not with dread, but as a natural law of life.
Most people, however, fear death. The drive to preserve life is an innate instinct of all living things, so one could say that humans, as biological beings, harbor this most fundamental and universal desire. Yet looking at animals that live vastly longer than we do, we sometimes feel that human life is far too brief. There is one person who has harbored that very thought seriously for a long time.
That person is Peter Thiel, the godfather of the PayPal Mafia and chairman of Palantir. Thiel believes that death is an obstacle fully within human capability to conquer. He held this conviction long before the recent explosion in technological advancement.
This is an essay Peter Thiel contributed to an American libertarian think tank in 2009. In it, Thiel explicitly declared his stance: he stands against the ideology of the inevitability of the death of every individual. Thiel is a staunch libertarian. He perceives death as a limitation that restrains human freedom and firmly believes that to achieve authentic libertarian values, we must overcome biological limitations, including death itself.
Let us journey back to San Francisco in 2004, shortly after Thiel sold PayPal. Thiel was hosting a dinner party at his home with a large group of guests. The gathering brought together business leaders and experts across various fields, including scientists. Among them were Dr. Cynthia Kenyon, who discovered that a mutation in a single gene in the nematode
C. elegans
, which normally lives for just 20 days, could double its lifespan, and Aubrey de Grey, a biogerontologist who argued that humans could live to be 1,000 years old.
Thiel engaged in an intense debate with these two scientists alongside Google co-founder Larry Page. A profound discussion unfolded over whether death is truly an inescapable inevitability or an engineering problem that science and technology can solve. While the exact details of the exchange remain private, Thiel subsequently made the decision to write substantial checks to both researchers. From that moment on, Thiel has continuously funded research aimed at conquering death.
More than 20 years have passed since that evening, yet Thiel's conviction remains unshaken. Although critics often dismiss the conquest of death as a pipe dream, Thiel remains undeterred. Even on recent podcasts, he continues to advocate for eternal life.
Peter Thiel is far from the only one; prominent figures across Big Tech have steadily invested in biotechnology startups. A prime example is Altos Labs, in which Amazon founder Jeff Bezos is known to have participated as an investor. Google took it a step further by establishing Calico, an affiliated life-extension research venture. Notably, Dr. Cynthia Kenyon, who previously debated with Thiel, serves as the vice president of aging research at Calico.
Backing has also arrived from newly emergent moguls who amassed fortunes in cryptocurrency and artificial intelligence. NewLimit, led by the founders of Coinbase, is investigating ways to restore aged cells to a youthful state. OpenAI CEO Sam Altman personally provided the entire initial funding for a startup named Retro Biosciences.
As this momentum builds, capital flowing into longevity biotechnology continues to swell.
According to data published in September this year, investment in longevity biotechnology, which stood at $4.7 billion in 2024, surged to $18.4 billion last year. Although this year is still underway, investment has already reached $12.1 billion.
Turning Back the Cellular Clock? Human Clinical Trials Have Already Begun
How exactly could we overcome death and reverse the aging process?
The catalyst for contemporary aging research was the pioneering work of Japanese scientist Shinya Yamanaka. Yamanaka demonstrated that introducing four transcription factors—proteins that regulate gene expression—into mouse somatic cells could revert them to a pluripotent stem cell-like state. Stem cells are unspecialized cells capable of differentiating into any cell type. Having developed induced pluripotent stem cells (iPSCs) using transcription factors, Yamanaka was awarded the 2012 Nobel Prize alongside British professor John Gurdon, who pioneered nuclear reprogramming. Through this discovery, humanity learned how to reset the fate of mature cells that were already executing specialized functions.
Intriguingly, researchers noticed that cells appeared biologically rejuvenated before fully reverting into stem cells. This prompted scientists to design experiments that turn back the cellular clock without rewinding cells completely into undifferentiated stem cells.
Researchers conducted an experiment activating the four Yamanaka factors in mice with progeria, a condition causing premature aging far faster than in normal mice. By applying cyclical treatment—activating the factors for 2 days followed by a 5-day resting period—the median survival age of the progeric mice surged by 33.3%, increasing from 18 weeks to 24 weeks.
Having confirmed in animal models that the cellular clock can be turned back, scientists have now expanded their research to human cells.
In 2020, the cover of
Nature
featured an illustration alongside the headline "Turning back time." A research team led by David Sinclair of Harvard University announced that they had reversed the aging of human optic nerves and restored visual function in mice.
A biotechnology startup co-founded by Sinclair subsequently announced plans to conduct human clinical trials this year. On October 8, the company disclosed preliminary findings from a clinical study involving three patients suffering from open-angle glaucoma. All three patients tolerated the treatment without side effects during an 8-week observation period, with two showing measurable visual field improvements.
Research utilizing AI technologies to reverse the cellular clock is also advancing at a rapid pace. The original Yamanaka factors represent just one specific combination discovered by Professor Yamanaka among myriad possibilities. The human genome encodes approximately 1,600 transcription factors, making it practically impossible to test every conceivable permutation manually to discover which combination rewinds cellular age. NewLimit, established by the founders of Coinbase, aims to pinpoint those ideal configurations through AI.
OpenAI is pursuing another avenue to tackle aging through AI in partnership with Retro Biosciences. While NewLimit leverages AI to discover entirely novel combinations, Retro Biosciences uses AI to modify and optimize existing Yamanaka factors to amplify rejuvenation efficacy.
If these efforts succeed, will true immortality become possible? If we can rewind the cellular clock and reset cell age, will Peter Thiel's vision be realized? A recent study concluded that this remains improbable. Conducted jointly by researchers from the Skolkovo Institute of Science and Technology and the Artificial Intelligence Research Institute in Russia, the study indicates that even if exponential medical breakthroughs reverse nearly all age-related damage, the human median lifespan will encounter a ceiling around 150 years.
Under standard aging trajectories, the median human lifespan is calculated at approximately 79 years, with a maximum lifespan around 107 years. What would happen under an idealized future scenario with advanced medical technology? Even assuming all other biological aging processes were eliminated, the median lifespan was projected at roughly 156 years, with a theoretical maximum lifespan of about 470 years. The researchers emphasize the hard boundary imposed by somatic mutations.
Somatic mutations are genetic alterations that occur when cells replicate DNA during cell division or repair daily cellular damage. Over time, these mutations inexorably accumulate, damaging cells and degrading their function. Crucially, post-mitotic cells such as neurons in our brains and cardiomyocytes in our hearts cannot easily be replaced once lost. If these tissues accumulate a large number of mutated cells, the damage remains irreversible. Even if advanced technology reverses conventional wear and tear, somatic mutations gathered over a lifetime present an insurmountable biological wall.
Despite these physiological limitations highlighted within and beyond academia, the longevity industry continues to expand rapidly. Why is this happening?
The Real Reason Big Money Is Diving into Life Extension
One could adopt the optimistic view that time will resolve technical hurdles. Nevertheless, it remains true that definitive, transformative clinical outcomes have yet to materialize. Halting aging, rewinding it, or conquering death altogether remains a long road ahead.
Why, then, is capital pouring into the field? Some argue that the industry thrives on the Silicon Valley elite's desire for eternal life. For those who have accumulated colossal wealth, virtually everything money can buy is already within reach. They can dine on the finest food and access premier healthcare. What remains for them to desire? In the end, only one ambition endures: living as long as possible, perhaps forever. This is why some observers remark that "immortality" has become Silicon Valley's newest religion.
Yet the sheer volume of capital flooding into the sector suggests that the personal aspirations of the wealthy are not the sole driver. Hard-nosed entrepreneurs rarely deploy billions lightly. From their perspective, they are investing because they see a profoundly lucrative market opportunity.
First and foremost, the aging sector possesses an ever-expanding customer base. Across the globe, population aging is accelerating. The World Health Organization projects that by 2030, one in six people worldwide will be aged 60 or older. While the global population aged 60 and over is projected to reach 1.4 billion by 2030, that figure is expected to surge to 2.1 billion by 2050. These older demographics allocate massive financial resources toward treating conditions that accompany aging.
Diseases whose incidence rises sharply with advancing age are classified as "age-related diseases." Researchers have found that these conditions account for more than half of the total disease burden among adults worldwide. This burden is not confined to wealthy nations; it accounts for roughly half of adult disease burdens across high-income and low-income countries alike.
What if, instead of tackling individual diseases one by one, therapies could target the root mechanism of aging itself? From a commercial standpoint, entrepreneurs would capture an addressable market with virtually no ceiling. That is precisely the prize investors are pursuing.
The vision of conquering death may indeed remain a dream. However, as societies age rapidly and age-related ailments consume half of global health burdens, commercializing technologies that merely slow down or partially reverse aging would unleash an impact of staggering proportions. While Peter Thiel's grand aspiration might seem fanciful, the capital flowing toward it is guided by sober economic calculations. Will humanity ever defeat death, or will we merely master the art of living a little longer? That concludes today's edition of OhGraph. Thank you very much for reading this in-depth piece.
References
- 「Peter Thiel: The AI Crisis, Europe's Decline & the Battle for America」 | MDMEETS - Essential Talks with Mathias Döpfner
- AnAge: The Animal Ageing and Longevity Database | Human Ageing Genomic Resources
- Oldest person ever: 122-year-old Jeanne Calment's extraordinary life | Guinness World Records
- All the unflattering things oldest person ever Jeanne Calment said about Vincent van Gogh | Guinness World Records
- The Education of a Libertarian | Peter Thiel
- Longevity Biotech Report 2026 | Longevity.Technology
- Ocampo et al., 「In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming」, Cell, 2016
- Turning back time | Nature
- Lu et al., 「Reprogramming to recover youthful epigenetic information and restore vision」, Nature, 2020
- Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies | Life Biosciences
- Accelerating life sciences research | OpenAI
- Efimov et al., 「Somatic mutations impose an entropic upper bound on human lifespan」, npj Aging, 2026
- Ageing and health | World Health Organization
- Chang et al., 「Measuring population ageing: an analysis of the Global Burden of Disease Study 2017」, The Lancet Public Health, 2019
Written by
An Hyemin
Designed by
Ahn Jun-seok
Intern
Shin Yeon-seong
※
Copying, redistribution, and unauthorized use in AI training are strictly prohibited.